Literature DB >> 16291929

Rapid disease progression correlates with instability of mutant SOD1 in familial ALS.

T Sato1, T Nakanishi, Y Yamamoto, P M Andersen, Y Ogawa, K Fukada, Z Zhou, F Aoike, F Sugai, S Nagano, S Hirata, M Ogawa, R Nakano, T Ohi, T Kato, M Nakagawa, T Hamasaki, A Shimizu, S Sakoda.   

Abstract

Studies on the clinical course of familial ALS suggest that the duration of illness is relatively consistent for each mutation but variable among the different mutations. The authors analyzed the relative amount of mutant compared with normal SOD1 protein in the erythrocytes from 29 patients with ALS with 22 different mutations. Turnover of mutant SOD1 correlated with a shorter disease survival time.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16291929     DOI： 10.1212/01.wnl.0000188760.53922.05

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


  19 in total

1.  SOD1 mutations targeting surface hydrogen bonds promote amyotrophic lateral sclerosis without reducing apo-state stability.

Authors:  Roberth Byström; Peter M Andersen; Gerhard Gröbner; Mikael Oliveberg
Journal:  J Biol Chem       Date:  2010-02-26       Impact factor: 5.157

2.  The effect of mutant SOD1 dismutase activity on non-cell autonomous degeneration in familial amyotrophic lateral sclerosis.

Authors:  Lijun Wang; Kamal Sharma; Gabriella Grisotti; Raymond P Roos
Journal:  Neurobiol Dis       Date:  2009-05-12       Impact factor: 5.996

3.  Superoxide dismutase 1 and tgSOD1 mouse spinal cord seed fibrils, suggesting a propagative cell death mechanism in amyotrophic lateral sclerosis.

Authors:  Ruth Chia; M Howard Tattum; Samantha Jones; John Collinge; Elizabeth M C Fisher; Graham S Jackson
Journal:  PLoS One       Date:  2010-05-13       Impact factor: 3.240

4.  Novel antibodies reveal inclusions containing non-native SOD1 in sporadic ALS patients.

Authors:  Karin Forsberg; P Andreas Jonsson; Peter M Andersen; Daniel Bergemalm; Karin S Graffmo; Magnus Hultdin; Johan Jacobsson; Roland Rosquist; Stefan L Marklund; Thomas Brännström
Journal:  PLoS One       Date:  2010-07-14       Impact factor: 3.240

5.  Selective association of misfolded ALS-linked mutant SOD1 with the cytoplasmic face of mitochondria.

Authors:  Christine Vande Velde; Timothy M Miller; Neil R Cashman; Don W Cleveland
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-22       Impact factor: 11.205

6.  Revisiting oxidative damage in ALS: microglia, Nox, and mutant SOD1.

Authors:  Séverine Boillée; Don W Cleveland
Journal:  J Clin Invest       Date:  2008-02       Impact factor: 14.808

7.  Common molecular signature in SOD1 for both sporadic and familial amyotrophic lateral sclerosis.

Authors:  Arie Gruzman; William L Wood; Evgenia Alpert; M Dharma Prasad; Robert G Miller; Jeffery D Rothstein; Robert Bowser; Ronald Hamilton; Troy D Wood; Don W Cleveland; Vishwanath R Lingappa; Jian Liu
Journal:  Proc Natl Acad Sci U S A       Date:  2007-07-16       Impact factor: 11.205

8.  Schwann cells expressing dismutase active mutant SOD1 unexpectedly slow disease progression in ALS mice.

Authors:  Christian S Lobsiger; Severine Boillee; Melissa McAlonis-Downes; Amir M Khan; M Laura Feltri; Koji Yamanaka; Don W Cleveland
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-27       Impact factor: 11.205

9.  Accelerated disease onset with stabilized familial amyotrophic lateral sclerosis (ALS)-linked mutant TDP-43 proteins.

Authors:  Shoji Watanabe; Kumi Kaneko; Koji Yamanaka
Journal:  J Biol Chem       Date:  2012-12-12       Impact factor: 5.157

10.  Defining SOD1 ALS natural history to guide therapeutic clinical trial design.

Authors:  Taha Bali; Wade Self; Jingxia Liu; Teepu Siddique; Leo H Wang; Thomas D Bird; Elena Ratti; Nazem Atassi; Kevin B Boylan; Jonathan D Glass; Nicholas J Maragakis; James B Caress; Leo F McCluskey; Stanley H Appel; James P Wymer; Summer Gibson; Lorne Zinman; Tahseen Mozaffar; Brian Callaghan; April L McVey; Jennifer Jockel-Balsarotti; Peggy Allred; Elena R Fisher; Glenn Lopate; Alan Pestronk; Merit E Cudkowicz; Timothy M Miller
Journal:  J Neurol Neurosurg Psychiatry       Date:  2016-06-03       Impact factor: 10.154
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.